ArticleMolecular and cellular biochemistry2017
Chemoprotective and chemosensitizing properties of selenium nanoparticle (Nano-Se) during adjuvant therapy with cyclophosphamide in tumor-bearing mice.
Article in Molecular and cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Nutritional perspectives for the prevention and mitigation of COVID-19.Nutrition reviews · 2021Pooled it
- Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Green synthesized selenium nanoparticles mitigate cyclophosphamide-induced reproductive toxicity in male Wistar rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Evaluating the anticancer efficacy of Chara vulgaris ethanolic extract and selenium nanoformulation in Ehrlich carcinoma mice: role of autophagy and apoptosis.BMC biotechnology · 2025Article
- Evaluating the efficacy of Rose Bengal-PVA combinations within PCL/PLA implants for sustained cancer treatment.Drug delivery and translational research · 2025Article
- Synthesis and Biomedical Based Applications of Selenium Nanoparticles: A Comprehensive Review.Indian journal of microbiology · 2025Article
- Plant Extracts for Production of Functionalized Selenium Nanoparticles.Materials (Basel, Switzerland) · 2024Review
- Nanoselenium attenuates renal ischemia-reperfusion injury in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Nanoparticle Formulations of Antioxidants for the Management of Oxidative Stress in Stroke: A Review.Biomedicines · 2023Review
- A Review of the Antibacterial, Fungicidal and Antiviral Properties of Selenium Nanoparticles.Materials (Basel, Switzerland) · 2023Review
- Biogenic Selenium Nanoparticles in Biomedical Sciences: Properties, Current Trends, Novel Opportunities and Emerging Challenges in Theranostic Nanomedicine.Nanomaterials (Basel, Switzerland) · 2023Review
- Biogenic Selenium Nanoparticles and Their Anticancer Effects Pertaining to Probiotic Bacteria-A Review.Antioxidants (Basel, Switzerland) · 2022Review
- Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2022Article
- Radiolytic synthesis and characterization of selenium nanoparticles: comparative biosafety evaluation with selenite and ionizing radiation.World journal of microbiology & biotechnology · 2022Article
- Prediagnostic Blood Selenium Status and Mortality among Patients with Colorectal Cancer in Western European Populations.Biomedicines · 2021Article
- The Advancing of Selenium Nanoparticles Against Infectious Diseases.Frontiers in pharmacology · 2021Review
- Evaluation of nanoselenium and nanogold activities against murine intestinal schistosomiasis.Saudi journal of biological sciences · 2019Article
- Protective role of nano-selenium-enrichedRoyal Society open science · 2018Article
- Selenium as a pleiotropic agent for medical discovery and drug delivery.International journal of nanomedicine · 2018Review
- Biogenic selenium and its hepatoprotective activity.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide (CP) is one of the widely used anticancer agents; however, it has serious deleterious effects on normal host cells due to its nonspecific action. The essential trace element Selenium (Se) is suggested to have chemopreventive and chemotherapeutic efficacy and currently used in pharmaceutical formulations. Previous report had shown Nano-Se could protect CP-induced hepatotoxicity and genotoxicity in normal Swiss albino mice; however, its role in cancer management is still not clear. The aim of present study is to investigate the chemoprotective efficacy of Nano-Se against CP-induced toxicity as well as its chemoenhancing capability when used along with CP in Swiss albino mice against Ehrlich's ascites carcinoma (EAC) cells. CP was administered (25 mg/kg b.w., i.p.) and Nano-Se was given (2 mg Se/kg b.w., p.o.) in concomitant and pretreatment schedule. Increase levels of serum hepatic marker, hepatic lipid peroxidation, DNA damage, and chromosomal aberration in CP-treated mice were significantly (P < 0.05) reversed by Nano-Se. The lowered status of various antioxidant enzymes in tumor-bearing mice after CP treatment was also effectively increased by Nano-Se. Administration of Nano-Se along with CP caused a significant reduction in tumor volume, packed cell volume, viable tumor cell count, and increased the survivability of the tumor-bearing hosts. The results suggest that Nano-Se exhibits significant antitumor and antioxidant effects in EAC-bearing mice. The potential for Nano-Se to ameliorate the CP-evoked toxicity as well as to improve the chemotherapeutic effect could have beneficial implications for patients undergoing chemotherapy with CP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.